Which beta-blocker combination has demonstrated mortality benefit in heart failure with reduced ejection fraction?

Which beta-blocker combination has demonstrated mortality benefit in heart failure with reduced ejection fraction?

• A. Atenolol, Nadolol, Propranolol
• B. Propranolol, Nadolol, Carvedilol
• C. Carvedilol, Bisoprolol, Metoprolol succinate
• D. Nebivolol

Answer: (C)

In heart failure with reduced ejection fraction, only certain beta-blockers have been shown to improve survival in large randomized trials. The ones with proven mortality benefit are carvedilol, bisoprolol, and metoprolol succinate. The reason this combination is the best answer is that it includes all three drugs that have demonstrated a survival advantage in HFrEF, based on pivotal studies like MERIT-HF (metoprolol succinate), CIBIS-II (bisoprolol), and trials with carvedilol (including COPERNICUS and others). Nebivolol, while studied in elderly heart failure patients, did not show a clear mortality benefit across the broader HFrEF population in the major trials, so it isn’t part of the standard trio proven to reduce death. The older beta-blockers such as atenolol, nadolol, and propranolol have not demonstrated the same level of mortality reduction in HFrEF trials, so they are not the best choice when aiming for proven survival benefit in this condition. So, the combination of carvedilol, bisoprolol, and metoprolol succinate represents the beta-blockers with demonstrated mortality benefit in HFrEF.

In heart failure with reduced ejection fraction, only certain beta-blockers have been shown to improve survival in large randomized trials. The ones with proven mortality benefit are carvedilol, bisoprolol, and metoprolol succinate. The reason this combination is the best answer is that it includes all three drugs that have demonstrated a survival advantage in HFrEF, based on pivotal studies like MERIT-HF (metoprolol succinate), CIBIS-II (bisoprolol), and trials with carvedilol (including COPERNICUS and others).

Nebivolol, while studied in elderly heart failure patients, did not show a clear mortality benefit across the broader HFrEF population in the major trials, so it isn’t part of the standard trio proven to reduce death. The older beta-blockers such as atenolol, nadolol, and propranolol have not demonstrated the same level of mortality reduction in HFrEF trials, so they are not the best choice when aiming for proven survival benefit in this condition.

So, the combination of carvedilol, bisoprolol, and metoprolol succinate represents the beta-blockers with demonstrated mortality benefit in HFrEF.